GreenLight Biosciences Holdings (GRNA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
GreenLight Biosciences Holdings (GRNA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has GreenLight Biosciences Holdings ever had a stock split?
GreenLight Biosciences Holdings Profile
| Biotechnology Industry | Healthcare Sector | Andrey Juan Zarur CEO | NASDAQ (NMS) Exchange | 39536G105 CUSIP |
| US Country | 280 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
GreenLight Biosciences Holdings is a pioneering biotechnology company dedicated to the advancement and commercialization of ribonucleic acid (RNA) products. Founded in 2008 and headquartered in Medford, Massachusetts, the company specializes in innovative RNA solutions tailored to address both human health and agricultural challenges. In the realm of human medicine, GreenLight focuses on developing mRNA-based vaccines and a range of therapeutic treatments. Concurrently, within the agricultural sector, the company offers RNA-targeted products designed to protect honeybee populations and ensure the integrity of cultivated crops.
Products and Services
- mRNA-based Vaccines
These vaccines leverage messenger RNA technology to stimulate an immune response against various infectious diseases, providing a modern approach to vaccination that can be swiftly adapted in response to emerging health threats.
- Therapeutic Treatments
GreenLight offers a variety of RNA-centric therapies aimed at targeting specific diseases, significantly enhancing treatment options and efficacy for patients with chronic or complex health conditions.
- RNA-driven Agricultural Products
The company develops RNA solutions specifically engineered to protect honeybee populations, which are crucial for pollination and biodiversity, as well as products designed to safeguard cultivated crops against pests and environmental stressors.
